# A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen

> **NCT00623831** · PHASE1 · COMPLETED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 17 (actual)

## Conditions studied

- Melanoma
- Sarcoma
- Gastrointestinal Stromal Tumor (GIST)
- Head and Neck Cancer
- Transitional Cell Carcinoma
- Prostate Cancer
- Ovarian Carcinoma
- Esophageal Cancer
- Breast Cancer

## Interventions

- **BIOLOGICAL:** Mixed bacterial vaccine

## Key facts

- **NCT ID:** NCT00623831
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2012-05
- **Final completion:** 2013-05
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2022-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00623831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00623831, "A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00623831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*